Recent Updates — ADXN
Addex Therapeutics issued 93,000,000 new registered shares at a nominal value of CHF 0.01 to its wholly-owned subsidiary, Addex Pharma S.A., under an existing capital band. The transaction increases the company's total issued share capital to CHF 3,116,544.96 representing 311,654,496 shares, while leaving the number of outstanding shares unchanged. The move is intended to provide additional future financing flexibility for the clinical-stage biopharmaceutical company focused on developing small molecule allosteric modulators for neurological disorders.
Addex Therapeutics announced executive management changes on October 2, 2026. Jean-Philippe Rocher was appointed Head of Pharmaceutical Development and member of the Executive Management, returning to the company after previously establishing its chemistry capabilities and serving at Neurosterix. Mikhail Kalinichev stepped down as Head of Translational Science to focus on a similar role at Neurosterix. Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders.
Addex Therapeutics reported a net loss of CHF 3.5 million for the first half of 2026, driven by operating expenses and a CHF 2.3 million share of losses from its Neurosterix equity investment. The company raised USD 2.8 million through an At-the-Market offering in August 2026. Addex regained rights to its GABAB PAM substance use disorder program from Indivior following their merger with Supernus Pharmaceuticals, while continuing preclinical development of a chronic cough candidate. Neurosterix is on track to complete Phase 1 trials for NTX-253 in schizophrenia by Q4 2026. The company operates as a clinical-stage biopharmaceutical firm developing small molecule allosteric modulators for neurological disorders.
Addex Therapeutics regained full global rights to all GABAB positive allosteric modulator assets from Indivior following the latter's rationalization of R&D activities and planned merger with Supernus Pharmaceuticals. This termination grants Addex ownership of a returned development candidate for substance use disorders, which has completed IND enabling studies, alongside its proprietary chronic cough program. The company now holds one of the broadest portfolios targeting GABAB receptor biology, with potential applications in pain, overactive bladder, and neurodevelopmental disorders. Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders.
Addex Therapeutics raised USD 2.8 million in gross proceeds through the sale of 437,869 ADSs representing 52,544,280 shares under its At-the-Market (ATM) agreement with H.C. Wainwright & Co. This capital raise extends the company's cash runway to the fourth quarter of 2027 and increases the outstanding share count to 210,292,217. Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders.